Journal of Leukocyte Biology Myeloid cells, immune suppression, tumor immunology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on August 1, 2004

Published online before print March 23, 2004
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.1203605v1
76/2/300    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ludewig, B.
Right arrow Articles by Scandella, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ludewig, B.
Right arrow Articles by Scandella, E.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.1203605

Received for publication December 1, 2003.
Revised February 12, 2004.
Accepted for publication February 16, 2004.

Article

Immunopathogenesis of atherosclerosis

Burkhard Ludewig @, Philippe Krebs , and Elke Scandella

Research Department, Kantonal Hospital St. Gallen, Switzerland

@ To whom correspondence should be addressed. E-mail: Burkhard.Ludewig{at}kssg.ch.


  Abstract

Recent clinical studies indicate that the number of microbial infections (the "pathogen burden") critically determines the development and progression of atherosclerotic disease. Viruses or bacteria with a specific tropism for cells of the vascular wall may contribute to the initial vascular injury via direct cytopathic effects or via the induction of genuine autoimmune responses. Immunopathological processes such as molecular mimicry, epitope spreading, or bystander activation of self-reactive lymphocytes most likely fuel the chronic inflammatory process in the vascular wall. Recognition of atherogenesis as a pathogen-driven, immunopathological process makes this disease amenable to new treatment strategies such as vaccination or immunomodulation.

Key Words: immunopathology • bystander activation • molecular mimicry • transgenic mouse model




This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
P. Krebs, E. Scandella, B. Bolinger, D. Engeler, S. Miller, and B. Ludewig
Chronic Immune Reactivity Against Persisting Microbial Antigen in the Vasculature Exacerbates Atherosclerotic Lesion Formation
Arterioscler. Thromb. Vasc. Biol., October 1, 2007; 27(10): 2206 - 2213.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H. Methe and M. Weis
Atherogenesis and inflammation--was Virchow right?
Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1823 - 1827.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Hasebe, N. D. Pennock, H.-H. Mu, F. V. Chan, M. L. Taylor, and B. C. Cole
A Microbial TLR2 Agonist Imparts Macrophage-Activating Ability to Apolipoprotein A-1
J. Immunol., October 1, 2006; 177(7): 4826 - 4832.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. J. Klebanoff
Myeloperoxidase: friend and foe
J. Leukoc. Biol., May 1, 2005; 77(5): 598 - 625.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Napoli, O. Pignalosa, F. de Nigris, and V. Sica
Childhood Infection and Endothelial Dysfunction: A Potential Link in Atherosclerosis?
Circulation, April 5, 2005; 111(13): 1568 - 1570.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2004 by the Society for Leukocyte Biology.